Dose escalation of ara-c may improve response rates in a subgroup of chronic myeloid leukemia patients with poor response to interferon-alpha and low-dose ara-C
The present analysis was performed to evaluate the impact of cytosine arabinoside (ara-C) dose escalation on hematological and cytogenetic responses in patients with chronic myelogenous leukemia (CML) who failed to respond to low-dose ara-C (LD ara-C) at a dose of 10 mg/m2/d over 10 days per month a...
Gespeichert in:
| Veröffentlicht in: | Leukemia & lymphoma 2001-11, Vol.42 (6), p.1283-1288 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1288 |
|---|---|
| container_issue | 6 |
| container_start_page | 1283 |
| container_title | Leukemia & lymphoma |
| container_volume | 42 |
| creator | Hilbe, W Kühr, T Apfelbeck, U Fridrik, M Seewann, H Stöger, M Linkesch, W Pont, J Baldinger, C Hartner, E Bernhart, M Geissler, D Krieger, O Lang, A Lin, W Ludwig, H Duba, C Greil, R Gast, G Thaler, J |
| description | The present analysis was performed to evaluate the impact of cytosine arabinoside (ara-C) dose escalation on hematological and cytogenetic responses in patients with chronic myelogenous leukemia (CML) who failed to respond to low-dose ara-C (LD ara-C) at a dose of 10 mg/m2/d over 10 days per month and interferon-alpha (IFNalpha, 3.5 MU/d). Following the same administration schedule, dose escalation of ara-C to 15 and 20 mg/m2/d 1-10 was performed in 36 of 119 patients (30%) due to inadequate hematological response and/or disease progression. As a result, improvement of hematological and cytogenetic responses was achieved in 22 (61%) and nine (25%) patients, respectively. Escalated ara-C dose levels were usually well tolerated, although some patients experienced deterioration of preexisting side effects. Our results support the critical role of ara-C dose towards a better disease control in CML. |
| doi_str_mv | 10.1080/10428190127503 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1080_10428190127503</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>11911409</sourcerecordid><originalsourceid>FETCH-LOGICAL-c293t-9fbbaa49ddc140c3ed763e4386502cf75b91a9ff85608667d10b57a4e69018283</originalsourceid><addsrcrecordid>eNpVkMtOwzAQRS0EoqWwZYn8Ayl-5OUlKk-pEhtYVxNnTANJbNkJqH_Dp-KolSpWM9Lcc3XnEnLN2ZKzkt1yloqSK8ZFkTF5QuacCZWIlMnTaU9FEq_pjFyE8MkYy1QuzsmMc8V5ytSc_N7bgBSDhhaGxvbUGgoeEk072NGmc95-I_UYnO2j0MOAgTY9BRrG6sPb0U2E3nrbN5HZYWubmrY4fmHXAHXRFPsh0J9m2FJnrT96DTYaDegNRjiB1m2BQh9h-5PUU6opx-qSnBloA14d5oK8Pz68rZ6T9evTy-punWih5JAoU1UAqaprHR_TEusil5jKMs-Y0KbIKsVBGVNmOSvzvKg5q7ICUsxjd6Uo5YIs977a2xA8mo3zTQd-t-FsM1W9-V91BG72gBurDuuj_NCt_AO_bXuD</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Dose escalation of ara-c may improve response rates in a subgroup of chronic myeloid leukemia patients with poor response to interferon-alpha and low-dose ara-C</title><source>MEDLINE</source><source>Taylor & Francis Medical Library - CRKN</source><source>Taylor & Francis Journals Complete</source><creator>Hilbe, W ; Kühr, T ; Apfelbeck, U ; Fridrik, M ; Seewann, H ; Stöger, M ; Linkesch, W ; Pont, J ; Baldinger, C ; Hartner, E ; Bernhart, M ; Geissler, D ; Krieger, O ; Lang, A ; Lin, W ; Ludwig, H ; Duba, C ; Greil, R ; Gast, G ; Thaler, J</creator><creatorcontrib>Hilbe, W ; Kühr, T ; Apfelbeck, U ; Fridrik, M ; Seewann, H ; Stöger, M ; Linkesch, W ; Pont, J ; Baldinger, C ; Hartner, E ; Bernhart, M ; Geissler, D ; Krieger, O ; Lang, A ; Lin, W ; Ludwig, H ; Duba, C ; Greil, R ; Gast, G ; Thaler, J</creatorcontrib><description>The present analysis was performed to evaluate the impact of cytosine arabinoside (ara-C) dose escalation on hematological and cytogenetic responses in patients with chronic myelogenous leukemia (CML) who failed to respond to low-dose ara-C (LD ara-C) at a dose of 10 mg/m2/d over 10 days per month and interferon-alpha (IFNalpha, 3.5 MU/d). Following the same administration schedule, dose escalation of ara-C to 15 and 20 mg/m2/d 1-10 was performed in 36 of 119 patients (30%) due to inadequate hematological response and/or disease progression. As a result, improvement of hematological and cytogenetic responses was achieved in 22 (61%) and nine (25%) patients, respectively. Escalated ara-C dose levels were usually well tolerated, although some patients experienced deterioration of preexisting side effects. Our results support the critical role of ara-C dose towards a better disease control in CML.</description><identifier>ISSN: 1042-8194</identifier><identifier>EISSN: 1029-2403</identifier><identifier>DOI: 10.1080/10428190127503</identifier><identifier>PMID: 11911409</identifier><language>eng</language><publisher>United States</publisher><subject>Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Child ; Child, Preschool ; Cytarabine - administration & dosage ; Cytarabine - adverse effects ; Female ; Humans ; Interferon-alpha - administration & dosage ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy ; Male ; Middle Aged</subject><ispartof>Leukemia & lymphoma, 2001-11, Vol.42 (6), p.1283-1288</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c293t-9fbbaa49ddc140c3ed763e4386502cf75b91a9ff85608667d10b57a4e69018283</citedby><cites>FETCH-LOGICAL-c293t-9fbbaa49ddc140c3ed763e4386502cf75b91a9ff85608667d10b57a4e69018283</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11911409$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hilbe, W</creatorcontrib><creatorcontrib>Kühr, T</creatorcontrib><creatorcontrib>Apfelbeck, U</creatorcontrib><creatorcontrib>Fridrik, M</creatorcontrib><creatorcontrib>Seewann, H</creatorcontrib><creatorcontrib>Stöger, M</creatorcontrib><creatorcontrib>Linkesch, W</creatorcontrib><creatorcontrib>Pont, J</creatorcontrib><creatorcontrib>Baldinger, C</creatorcontrib><creatorcontrib>Hartner, E</creatorcontrib><creatorcontrib>Bernhart, M</creatorcontrib><creatorcontrib>Geissler, D</creatorcontrib><creatorcontrib>Krieger, O</creatorcontrib><creatorcontrib>Lang, A</creatorcontrib><creatorcontrib>Lin, W</creatorcontrib><creatorcontrib>Ludwig, H</creatorcontrib><creatorcontrib>Duba, C</creatorcontrib><creatorcontrib>Greil, R</creatorcontrib><creatorcontrib>Gast, G</creatorcontrib><creatorcontrib>Thaler, J</creatorcontrib><title>Dose escalation of ara-c may improve response rates in a subgroup of chronic myeloid leukemia patients with poor response to interferon-alpha and low-dose ara-C</title><title>Leukemia & lymphoma</title><addtitle>Leuk Lymphoma</addtitle><description>The present analysis was performed to evaluate the impact of cytosine arabinoside (ara-C) dose escalation on hematological and cytogenetic responses in patients with chronic myelogenous leukemia (CML) who failed to respond to low-dose ara-C (LD ara-C) at a dose of 10 mg/m2/d over 10 days per month and interferon-alpha (IFNalpha, 3.5 MU/d). Following the same administration schedule, dose escalation of ara-C to 15 and 20 mg/m2/d 1-10 was performed in 36 of 119 patients (30%) due to inadequate hematological response and/or disease progression. As a result, improvement of hematological and cytogenetic responses was achieved in 22 (61%) and nine (25%) patients, respectively. Escalated ara-C dose levels were usually well tolerated, although some patients experienced deterioration of preexisting side effects. Our results support the critical role of ara-C dose towards a better disease control in CML.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Cytarabine - administration & dosage</subject><subject>Cytarabine - adverse effects</subject><subject>Female</subject><subject>Humans</subject><subject>Interferon-alpha - administration & dosage</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy</subject><subject>Male</subject><subject>Middle Aged</subject><issn>1042-8194</issn><issn>1029-2403</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkMtOwzAQRS0EoqWwZYn8Ayl-5OUlKk-pEhtYVxNnTANJbNkJqH_Dp-KolSpWM9Lcc3XnEnLN2ZKzkt1yloqSK8ZFkTF5QuacCZWIlMnTaU9FEq_pjFyE8MkYy1QuzsmMc8V5ytSc_N7bgBSDhhaGxvbUGgoeEk072NGmc95-I_UYnO2j0MOAgTY9BRrG6sPb0U2E3nrbN5HZYWubmrY4fmHXAHXRFPsh0J9m2FJnrT96DTYaDegNRjiB1m2BQh9h-5PUU6opx-qSnBloA14d5oK8Pz68rZ6T9evTy-punWih5JAoU1UAqaprHR_TEusil5jKMs-Y0KbIKsVBGVNmOSvzvKg5q7ICUsxjd6Uo5YIs977a2xA8mo3zTQd-t-FsM1W9-V91BG72gBurDuuj_NCt_AO_bXuD</recordid><startdate>20011101</startdate><enddate>20011101</enddate><creator>Hilbe, W</creator><creator>Kühr, T</creator><creator>Apfelbeck, U</creator><creator>Fridrik, M</creator><creator>Seewann, H</creator><creator>Stöger, M</creator><creator>Linkesch, W</creator><creator>Pont, J</creator><creator>Baldinger, C</creator><creator>Hartner, E</creator><creator>Bernhart, M</creator><creator>Geissler, D</creator><creator>Krieger, O</creator><creator>Lang, A</creator><creator>Lin, W</creator><creator>Ludwig, H</creator><creator>Duba, C</creator><creator>Greil, R</creator><creator>Gast, G</creator><creator>Thaler, J</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20011101</creationdate><title>Dose escalation of ara-c may improve response rates in a subgroup of chronic myeloid leukemia patients with poor response to interferon-alpha and low-dose ara-C</title><author>Hilbe, W ; Kühr, T ; Apfelbeck, U ; Fridrik, M ; Seewann, H ; Stöger, M ; Linkesch, W ; Pont, J ; Baldinger, C ; Hartner, E ; Bernhart, M ; Geissler, D ; Krieger, O ; Lang, A ; Lin, W ; Ludwig, H ; Duba, C ; Greil, R ; Gast, G ; Thaler, J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c293t-9fbbaa49ddc140c3ed763e4386502cf75b91a9ff85608667d10b57a4e69018283</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Cytarabine - administration & dosage</topic><topic>Cytarabine - adverse effects</topic><topic>Female</topic><topic>Humans</topic><topic>Interferon-alpha - administration & dosage</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy</topic><topic>Male</topic><topic>Middle Aged</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hilbe, W</creatorcontrib><creatorcontrib>Kühr, T</creatorcontrib><creatorcontrib>Apfelbeck, U</creatorcontrib><creatorcontrib>Fridrik, M</creatorcontrib><creatorcontrib>Seewann, H</creatorcontrib><creatorcontrib>Stöger, M</creatorcontrib><creatorcontrib>Linkesch, W</creatorcontrib><creatorcontrib>Pont, J</creatorcontrib><creatorcontrib>Baldinger, C</creatorcontrib><creatorcontrib>Hartner, E</creatorcontrib><creatorcontrib>Bernhart, M</creatorcontrib><creatorcontrib>Geissler, D</creatorcontrib><creatorcontrib>Krieger, O</creatorcontrib><creatorcontrib>Lang, A</creatorcontrib><creatorcontrib>Lin, W</creatorcontrib><creatorcontrib>Ludwig, H</creatorcontrib><creatorcontrib>Duba, C</creatorcontrib><creatorcontrib>Greil, R</creatorcontrib><creatorcontrib>Gast, G</creatorcontrib><creatorcontrib>Thaler, J</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Leukemia & lymphoma</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hilbe, W</au><au>Kühr, T</au><au>Apfelbeck, U</au><au>Fridrik, M</au><au>Seewann, H</au><au>Stöger, M</au><au>Linkesch, W</au><au>Pont, J</au><au>Baldinger, C</au><au>Hartner, E</au><au>Bernhart, M</au><au>Geissler, D</au><au>Krieger, O</au><au>Lang, A</au><au>Lin, W</au><au>Ludwig, H</au><au>Duba, C</au><au>Greil, R</au><au>Gast, G</au><au>Thaler, J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dose escalation of ara-c may improve response rates in a subgroup of chronic myeloid leukemia patients with poor response to interferon-alpha and low-dose ara-C</atitle><jtitle>Leukemia & lymphoma</jtitle><addtitle>Leuk Lymphoma</addtitle><date>2001-11-01</date><risdate>2001</risdate><volume>42</volume><issue>6</issue><spage>1283</spage><epage>1288</epage><pages>1283-1288</pages><issn>1042-8194</issn><eissn>1029-2403</eissn><abstract>The present analysis was performed to evaluate the impact of cytosine arabinoside (ara-C) dose escalation on hematological and cytogenetic responses in patients with chronic myelogenous leukemia (CML) who failed to respond to low-dose ara-C (LD ara-C) at a dose of 10 mg/m2/d over 10 days per month and interferon-alpha (IFNalpha, 3.5 MU/d). Following the same administration schedule, dose escalation of ara-C to 15 and 20 mg/m2/d 1-10 was performed in 36 of 119 patients (30%) due to inadequate hematological response and/or disease progression. As a result, improvement of hematological and cytogenetic responses was achieved in 22 (61%) and nine (25%) patients, respectively. Escalated ara-C dose levels were usually well tolerated, although some patients experienced deterioration of preexisting side effects. Our results support the critical role of ara-C dose towards a better disease control in CML.</abstract><cop>United States</cop><pmid>11911409</pmid><doi>10.1080/10428190127503</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1042-8194 |
| ispartof | Leukemia & lymphoma, 2001-11, Vol.42 (6), p.1283-1288 |
| issn | 1042-8194 1029-2403 |
| language | eng |
| recordid | cdi_crossref_primary_10_1080_10428190127503 |
| source | MEDLINE; Taylor & Francis Medical Library - CRKN; Taylor & Francis Journals Complete |
| subjects | Adolescent Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - therapeutic use Child Child, Preschool Cytarabine - administration & dosage Cytarabine - adverse effects Female Humans Interferon-alpha - administration & dosage Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy Male Middle Aged |
| title | Dose escalation of ara-c may improve response rates in a subgroup of chronic myeloid leukemia patients with poor response to interferon-alpha and low-dose ara-C |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T05%3A02%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dose%20escalation%20of%20ara-c%20may%20improve%20response%20rates%20in%20a%20subgroup%20of%20chronic%20myeloid%20leukemia%20patients%20with%20poor%20response%20to%20interferon-alpha%20and%20low-dose%20ara-C&rft.jtitle=Leukemia%20&%20lymphoma&rft.au=Hilbe,%20W&rft.date=2001-11-01&rft.volume=42&rft.issue=6&rft.spage=1283&rft.epage=1288&rft.pages=1283-1288&rft.issn=1042-8194&rft.eissn=1029-2403&rft_id=info:doi/10.1080/10428190127503&rft_dat=%3Cpubmed_cross%3E11911409%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/11911409&rfr_iscdi=true |